

DEBATE

Open Access

Must we press on until a young mother dies? Remifentanil patient controlled analgesia in labour may not be suited as a “poor man’s epidural”

Peter Kranke^{1*}, Thierry Girard², Patricia Lavand’homme³, Andrea Melber⁴, Johanna Jokinen¹, Ralf M Muellenbach¹, Johannes Wirbelauer⁵ and Arnd Höning⁶

Abstract

Background: The epidural route is still considered the gold standard for labour analgesia, although it is not without serious consequences when incorrect placement goes unrecognized, e.g. in case of intravascular, intrathecal and subdural placements. Until now there has not been a viable alternative to epidural analgesia especially in view of the neonatal outcome and the need for respiratory support when long-acting opioids are used via the parenteral route. Pethidine and meptazinol are far from ideal having been described as providing rather sedation than analgesia, affecting the cardiotocograph (CTG), causing fetal acidosis and having active metabolites with prolonged half-lives especially in the neonate. Despite these obvious shortcomings, intramuscular and intravenously administered pethidine and comparable substances are still frequently used in delivery units. Since the end of the 90ths remifentanil administered in a patient-controlled mode (PCA) had been reported as a useful alternative for labour analgesia in those women who either don’t want, can’t have or don’t need epidural analgesia.

Discussion: In view of the need for conversion to central neuraxial blocks and the analgesic effect remifentanil has been demonstrated to be superior to pethidine. Despite being less effective in terms of the resulting pain scores, clinical studies suggest that the satisfaction with analgesia may be comparable to that obtained with epidural analgesia. Owing to this fact, remifentanil has gained a place in modern labour analgesia in many institutions. However, the fact that remifentanil may cause harm should not be forgotten when the use of this potent mu-agonist is considered for the use in labouring women. In the setting of one-to-one midwifery care, appropriate monitoring and providing that enough experience exists with this potent opioid and the treatment of potential complications, remifentanil PCA is a useful option in addition to epidural analgesia and other central neuraxial blocks. Already described serious consequences should remind us not refer to remifentanil PCA as a “poor man’s epidural” and to safely administer remifentanil with an appropriate indication.

Summary: Therefore, the authors conclude that economic considerations and potential cost-savings in conjunction with remifentanil PCA may not be appropriate main endpoints when studying this valuable method for labour analgesia.

Keywords: Remifentanil, Epidural Analgesia, Labour Pain, Labour Analgesia, Patient Controlled Analgesia, Patient Satisfaction, Healthcare Cost, Healthcare Economics

* Correspondence: kranke_p@klinik.uni-wuerzburg.de

¹Department of Anaesthesia and Critical Care, University Hospitals of Würzburg, Oberdürrbacher Str. 6, Würzburg 97080, Germany
Full list of author information is available at the end of the article

Background

Ideal labour analgesic will provide sustained pain relief for the time period when the parturient is in need for analgesia, but is flexible enough to be adjusted to the varying analgesic requirements throughout the labour process and wears off quickly, if analgesia is not needed any more following delivery. Furthermore, the ideal labour analgesia will have a low incidence of side effects for the mother and the baby and will be easy to institute irrespective of the resources and skills available to allow that all parturients who wish to experience significant pain relief actually receive effective analgesics. Moreover, the ideal labour analgesic may depend on the parturient and the individual preferences as well as expectations for the birth experience since maximum pain relief may not always be of utmost importance [1].

According to the guidelines of the American Society of Anesthesiologists (ASA) and the American College of Obstetricians and Gynecologists (ACOG), neuraxial analgesia techniques (epidural, spinal, and combined spinal-epidural) are recommended in labour as “the most flexible, effective, and least depressing to the central nervous system” of the choices available and thus “allowing for an alert participating woman and an alert neonate” [2].

Similar statements and recommendations exist on national levels. The recommendation of the German Society of Anaesthesia and Intensive Care, for instance, states that central neuraxial regional analgesia and anaesthesia are especially safe and effective to provide adequate pain relief in the peripartum period and for anaesthesia during cesarean section without leading to a relevant impairment of the vital signs of the newborn [3].

Owing to the fact that “maternal request is a sufficient medical indication for pain relief during labor”, the threshold to withhold effective pain relief is considerable high. This view is supported by the respective ACOG recommendations stating that: “Labor results in severe pain for many women. There is no other circumstance in which it is considered acceptable for a person to experience untreated severe pain, amenable to safe intervention, while under a physician’s care. In the absence of a medical contraindication, maternal request is a sufficient medical indication for pain relief during labor” [4].

These remarks are well in line with general statements on pain relief and represent the spirit of the Declaration of Montreal of the International Association for the Study of Pain (IASP), stating “that access to pain management is a fundamental human right” [5].

Bearing these essentials in mind – access to pain management as a fundamental human right and maternal request as a sufficient medical indication for pain relief during labour – it is self-evident, that for labouring women who either don’t want, can’t have or don’t (yet) need epidural analgesia, best suited alternative options

need to be provided in order to ensure that as much as possible factors, representing the “ideal labour analgesic” will be met.

The following discussion provides a short overview of current analgesic techniques available with special reference to intravenous remifentanyl, administered in a patient controlled manner. Further, suggestions for future topics of research with the intention to provide more solid data when and how its use should be recommended to ensure safety for mother and baby as an utmost clinical and medicolegal goal will be given. In addition, the discussion should raise awareness that the anesthesiologist in the delivery suite should not solely be regarded as a prerequisite to ensure labour analgesia via the epidural route but is equally important when it comes to risk assessment of the labouring woman and to ensure that emergency situations (including emergency cesarean section) can be adequately managed.

Last but not least the article should stimulate instructive discussions, whether cost-minimization represents a suitable approach to assess the suitability of alternatives to central neuraxial labour analgesia, as outlined and emphasized in a recently published study protocol in this journal [6].

Discussion

Long-acting parenterally administered opioid analgesics

Many parenterally administered opioid analgesics have been tested so far in the aim to provide alternatives for central neuraxial analgesia in the parturient, either for those parturients who do not wish to receive central neuraxial analgesia or in settings where methods of central neuraxial analgesia are not available or medically contraindicated.

The advantage of systemic analgesia may be that its use is not restricted to settings where health professionals being qualified to perform central neuraxial blocks are available and appropriate monitoring and the ability to cope with complications cannot be ensured. Unfortunately, despite extensive search for alternative options and long-lasting experience with various options, real competitive options to central neuraxial analgesia have not been elucidated so far.

Unlike in the postoperative or acute trauma setting, where pethidine has not a place any more [7], pethidine and meptazinol – and to a lesser degree morphine – still remain popular and widely used options for pain relief during labour. In view of the overall limited effect and well-recognized side-effects [8-10] the persisting dominance of these opioid analgesics remains striking. In a Norwegian survey published in 2009 pethidine was the most commonly used opioid analgesic, being administered in a nurse controlled fashion in 77% of the units who responded to the survey, while the epidural

frequency was only 26% [11]. The survey further found out that “Nurse-administrated analgesia was the method of choice for all units, either i.v. or intramuscular (i.m.)”. It was striking that in this survey fifty-eight per cent reported only i.m. administration, 8% i.v. and 34% both forms. A survey conducted in Germany only recently suggested that parenteral opioids remain a popular offer for women with labour pain [12]. Despite the fact that all departments responding to the survey provided a 24 h epidural service, “the most commonly used opioids were pethidine (19%), meptazinol (17%) and piritramide (16%) for intermittent intravenous/intramuscular administration” [12]. In case of the use of a PCA device to administer the analgesic, remifentanyl was already the most popular choice (68%).

It remains not only the choice of the drugs itself, but especially the route of administration that lacks scientific evidence and is considered outdated, e.g. in the postoperative period, to cope with acute pain [7]. What is already common practice in the postoperative care has not reached the delivery suites yet, with intramuscular route still being a popular route of administration. Although the evidence with any of these drugs given intravenously is much poorer than with the intramuscular route it remains unchallenged that “The intramuscular route is not recommended because it is not dependable – the rate of drug-absorption may vary. Intravenous administration is more reliable,....” These recommendations also apply to so-called “low-resource settings”, as the Chapter 17 on “Pharmacological Management of Pain in Obstetrics” of the IASP Guide to Pain Management in Low-Resource Settings points out [13].

The current evidence regarding parenteral opioids for labour pain is comprehensively summarized in a recent Cochrane Review that concluded “Parenteral opioids provide some relief from pain in labour but are associated with adverse effects. Maternal satisfaction with opioid analgesia was largely unreported but appeared moderate at best” [10].

More accentuated views are presented in the original trials that often suggest “that labour pain is not sensitive to systemically administered morphine or pethidine” and that “These drugs only cause heavy sedation. It therefore seems unethical and medically incorrect to meet parturients’ requests for pain relief by giving them sedation. Considering the well documented negative effects on newborn infants we also believe systemic pethidine should be avoided in labour” [8]. Single trials also report a rather short-lived effect of traditional opioids when they draw the conclusion that “Every woman receiving one injection of meptazinol complained of moderate to severe pain after 2 h; 97% of those receiving one injection of pethidine were complaining of moderate to severe pain after 2 h” [14].

And in a comparison with meptazinol, once introduced with the expectation to cause lower incidences of opioid adverse effects, Nel et al. who compared meptazinol and pethidine in a double-blind randomized trial with regard to analgesia during the first stage of labour as early as 1981 stated “... that neither drug is effective for sustained pain relief, and that there is no advantage of one over the other” and further remarked that “The critical reassessment of traditional drugs for analgesia in labour is suggested” [15].

Inhaled nitrous oxide

In view of the apparent need to have choice in pain relief and the frequently observed tendency to first opt for less invasive methods of pain relief, the popularity of inhaled analgesia is not surprising. The popularity of nitrous oxide varies from country to country. While it is used by about 60% of laboring women in the UK and is also frequently used in Australia and the Scandinavian countries [11-16], it is rarely available as an analgesic option in Germany or the USA.

In principle, these methods ensure that the mother stays awake and laryngeal reflexes remain intact. The fact that inhaled interventions for pain relief are usually easy to administer with limited preparation time and fast onset account for their popularity in some countries.

Recently, the existing body of evidence with respect to nitrous oxide and other inhaled molecules have been subjected to a systematic review in which the authors concluded that “Inhaled analgesia appears to be effective in reducing pain intensity and in giving pain relief in labour” [17]. However, these conclusions have been based mainly on the fact that placebo, sham-treatment or no treatment provided less pain relief compared to nitrous oxide (average RR 0.06, 95% CI 0.01 to 0.34, two studies, 310 women; MD -3.50, 95% CI -3.75 to -3.25, one study, 509 women). Based on the report of 8 controlled trials and in 8 observational studies another systematic review had summarized the findings of these trials in a systematic review slightly different, stating that “Nitrous oxide is not a potent labor analgesic, but it is safe for parturient women....” [18].

It goes without saying that even this ‘innocent’, because less invasive, intervention is associated with more side effects for women such as nausea (RR 43.10, 95% CI 2.63 to 706.74, one study, 509 women), vomiting (RR 9.05, 95% CI 1.18 to 69.32, two studies, 619 women), dizziness (RR 113.98, 95% CI 7.09 to 1833.69, one study, 509 women) and drowsiness (RR 77.59, 95% CI 4.80 to 1254.96, one study, 509 women) when compared with placebo or no treatment [17]. These findings support the notion, that it cannot be argued that such an intervention should be tried first, with the argument that no relevant adverse effects will occur. In addition it might

be important to note that nitrous oxide is a greenhouse gas and reacts with ozone. More recently there is increasing evidence of neuroapoptosis induced by anesthetic agents in the developing brain. The role of nitrous oxide in this context is unclear [19].

In a study hypothesizing that remifentanyl would provide better analgesia during labour than nitrous oxide, the authors compared intravenous remifentanyl in 0.4 µg/kg PCA doses with 1-min infusion and lock-out times with intermittent inhaled 50% nitrous oxide during a 20-min study period with a subsequent 20-min wash-out sequence after each period [20]. The main result had been that the “median decrease in pain score for remifentanyl was 1.5 and that for nitrous oxide 0.5 ($P=0.01$)” on a verbal numeric rating scale from 0 to 10. Furthermore, “the parturients gave better pain relief scores with remifentanyl than with nitrous oxide” with a median of 2.5 (remifentanyl) vs. 0.5 (nitrous oxide), respectively. In contrast to these more beneficial effects “sedation was reported more often, and SaO_2 was slightly lower during remifentanyl administration” Although blinding was ensured, most patients preferred the analgesia provided by remifentanyl to that provided by nitrous oxide (14 vs 1, out of 15 parturients who completed the study).

Remifentanyl

Remifentanyl is available on the market in Europe since the 90's. In Germany, being available since 1996, it is licensed to supplement general anaesthesia as a μ opioid agonist or for the use as analgesic in conjunction with sedation and analgesia on ICU. Although not very popular in clinical care, its use as analgesic in the postoperative period for the awake and spontaneous breathing patient is mentioned in the Summary of Product Characteristics (SPC). In this regard a continuous infusion (start with 0,1 µg/kg/min) is recommended in the SPC, while the administration of boluses in the spontaneous breathing patient is “not recommended” according to the wording of the SPC.

Owing to its unique pharmacokinetic properties with rapid metabolism by tissue esterase, its use has been quickly widened out to the use for labour analgesia, since for the first time in the history of opioid analgesia provided by the parenteral route “adequate doses of opioid (could be) administered to the mother to achieve good analgesia, without its accumulation in the fetus” [21,22] the use of remifentanyl has been extended from patients presenting with (relative) medical contraindications for neuraxial blockade to patients who refuse epidural analgesia (e.g. due to backache) [23] or to settings, where neuraxial analgesia is simply not available [24].

Concomitantly, the use of remifentanyl gained popularity for the supplementation of a general anaesthesia in

the cardiovascular compromised obstetric patient, e.g. aortic or valvular disease [25] or patients presenting with a cardiomyopathy [26].

Until now, the available published evidence suggests that even the administration of remifentanyl immediately before cord clamping (e.g. at induction of general anaesthesia for cesarean delivery) does not mean that the neonate is at significantly increased risk to need mask ventilation or tracheal intubation [27] although the studies looking at this outcome are limited and the event rate is still very low, limiting the conclusions that can be drawn. Furthermore, and owing to own experiences, these endpoints are highly variable with the experience and knowledge of the neonatal team caring for the newborn in that regard, that neonatologists knowing the substance and its unique pharmacokinetic profile tend to be more conservative regarding early airway interventions.

These encouraging data lead to the recommendation of national societies to supplement general anaesthesia with an adjunct to attenuate the cardiovascular response to intubation and skin incision in the parturient with preeclampsia [3].

The use of remifentanyl, though not uniformly supported by all available evidence, gained more and more popularity and is in routine use in some institutions, not only in cases where central neuraxial blocks are contraindicated [28,29].

The cumulative evidence suggests that compared with pethidine, its use for labour analgesia is associated with significantly improved pain relief and satisfaction and is associated with a significantly decreased conversion rate to epidural analgesia [30]. Trials comparing intravenous patient controlled analgesia using remifentanyl with epidural analgesia suggest – which is not a surprise – a more pronounced reduction in pain scores with neuraxial analgesia [30,31]. When it comes to overall satisfaction with the analgesic technique, however, the studies report that “Maternal satisfaction was similar” [31] or “Patient satisfaction scores during and after delivery were similar in both groups” [32].

In view of the neonatal outcome, the available evidence does not suggest a negative effect on the newborn. This is not surprising, considering the results obtained in clinical trials where remifentanyl had been administered immediately prior to cord clamping in conjunction with general anaesthesia for caesarean section [27].

Clearly, the potential to cause adverse effects as a potent μ -agonist must not be forgotten [33,34] and subsequently has raised concerns in view of its use for labour analgesia and evoked the provocative question used for this article: “Must we press on until a young mother dies?” [35]. The fact that labour analgesia is not a licensed indication may have further prevented its use in many institutions so far [36]. Although it has to be

emphasized – from a medicolegal point of view – that the lack of an indication (as stated in the SPC) is not a sufficient justification to withhold treatment. On the contrary! Knowing that alternative options – may be even safer or effective – do exist, would necessitate to inform patients accordingly and use such an intervention irrespective of its indication as stated by the manufacturer in the SPC [37-40].

Remifentanil – what we would like to know

Although in the meanwhile new evidence suggests that remifentanil will have a role to cope with labour pain [41], any new evidence to support its use and elucidate pitfalls and shortcomings may be welcome in order to promote a safe use and not harm the mother or neonate. This is especially true since, at least so far, there seems to be little agreement regarding the necessary monitoring during its use in the labour suite [12]. The latter is true also for other opioids, since these are associated with decreases in oxygen saturation, sedation and the need for oxygen administration as well [42].

Persistent pain following labour is an important socio-economic factor and has been found to be as frequent as 1 in 10 women [43]. On the other hand remifentanil has shown to possess a potential to cause opioid-induced hyperalgesia [44]. Therefore, the role of remifentanil PCIA in persistent and chronic pain following childbirth should be addressed in subsequent evaluations.

There is an ongoing discussion on the suitability of various regimens to administer remifentanil as labour analgesic. While some argue that a continuous background infusion may be helpful, others argue – in accordance with recommendations to ensure safety of opioid patient controlled analgesia in the postoperative setting [45] – that the avoidance of any background infusion may constitute an essential safety feature of this highly potent μ -opioid in that respect that any potential respiratory depression associated with a self-administered bolus should be short-lived.

In view of these recent developments, we were highly pleased to read the study protocol describing a randomised controlled trial investigating remifentanil patient controlled analgesia versus epidural analgesia during labour (RAVEL protocol) [6].

In a multicentre randomized controlled study performed at various Dutch hospitals the objective of the study “is to test the hypothesis that remifentanil PCA is as effective as epidural analgesia with respect to patient satisfaction and pain appreciation scores with lower costs and possibly benefit of easier achievement of 24 hours availability of pain relief for women in labour” [6].

We would like to challenge the assumption that overall costs and ease of administration are meaningful and sensible endpoints in this setting.

There is no doubt, that in principle and taking into account all costs of an epidural service and providing a stand-by service with an anesthesia team in general (contingency costs) costs more than simply providing a patient suffering from labour pain and requesting for pain relief with an intravenous PCIA-pump (patient controlled infusion pump). However, this assumption neglects the statement which is valid so far, that remifentanil PCIA should not be viewed as a full substitute for epidural analgesia and in many institutions that extensively practice this method of pain relief is viewed as complementary tool either for those cases not needing an epidural catheter or other forms of neuraxial pain relief or before changing to neuraxial analgesia [23,28,40].

Although it may be acknowledged that in low resource settings, the availability of remifentanil could attenuate suffering in conjunction with childbirth experience, this should not be the leading argument in developed countries, where standards have been established and birth rates are declining. In these settings, the primary aim should be to hold up the established standards in view of safety and to this aim, anaesthesiologists may contribute a lot more than simply inserting epidurals [46].

It goes without saying that the indication to prescribe remifentanil, at least when administered in analgesic doses necessary to obtain pain relief during labour, should stay in the hands of personnel having experiences with the substance and being able to cope with potential side effects.

Lastly, the obtained outcomes should be subject to a close quality control program to gain future insights and ensure that remifentanil retains its valuable place in the delivery suite.

To our knowledge there is only one published study, in which remifentanil was administered as a continuous infusion in a setting where no anaesthetist has been available. In view of the potential to cause harm [33], we would also challenge the general assumption, “that the presence of an anaesthetist for this type of analgesia is not required and that administration of remifentanil is quicker and less invasive than epidural analgesia” [6]. At least, this assumption contradicts the SPC in Germany, where high hurdles are stated in view of the personal that should be allowed to administer this potent opioid. We would rather agree with Tveit and colleagues stating that “Remifentanil intravenous patient-controlled analgesia provides adequate pain relief and high maternal satisfaction during the first and second stages of labour”. but also reminded us that “Maternal sedation and respiratory depression may occur...” and therefore “careful monitoring is mandatory” [47].

Owing to the fact that cost analyses are highly variable – consider for instance the performance of a MRI-Scan to

exclude epidural abscess or hematoma following epidural analgesia – we would assume that the outcome in terms of costs may yield any desired values depending on the models applied.

To our understanding the aim to assess the possible “benefit of easier achievement of 24 hours availability of pain relief for women in labour” [6] cannot be answered since an epidural service needs to be held available anyway due to the performed randomization to either the epidural or the remifentanil PCA group. Performing “epidural analgesia according to local protocol” [6] is a pragmatic design and per se not criticisable. However, considering the fact that “epidural analgesia” may imply quite different protocols, we suspect that this may render the comparison versus remifentanil highly variable with regard to the outcome “pain appreciation”.

The authors all use this form a labour analgesia and are convinced that it fits well into the armamentarium of labour analgesia available so far. More importantly, it constitutes an alternative for women who either don't want, can't have or don't (yet) need epidural analgesia or want to try an alternative option to central neuraxial analgesia first. Therefore, clinical trials and observational data assessing the risk for maternal fever, assessing the breastfeeding success, drop in oxygen saturation, satisfaction, APGAR values, Neurologic and Adaptive Capacity Score (NACS) amongst other well-established outcomes are welcome.

However, the authors are concerned that if the limitations of remifentanil PCA as a potent intervention are not strictly taken into account and economic reasoning is overbearing, we may put too much pressure on this valuable intervention to succeed and thus “press on until a young mother dies” [35].

John Snow, by royal invitation, used chloroform on Queen Victoria during the delivery of Prince Leopold on 7th April 1853. At that time, the medical establishment, in view of the reported side effects, and with an innate resistance to clinical advances, commented in the *Lancet* [48]: “Intense astonishment, therefore, has been excited throughout the profession by the rumour that her Majesty during her last labour was placed under the influence of chloroform, an agent which has unquestionably caused instantaneous death in a considerable number of cases. Doubts on this subject cannot exist”.

These caveats are nicely illustrated by anecdotal evidence about a Mr. Gladstone, who was Prime Minister at the time of Prince Leopold's birth. When he visited the sovereign to discuss affairs of state Gladstone congratulated the Queen on the addition to her family, and then asked her how she liked Dr Snow's chloroform. The Queen replied ‘Very well, Mr Gladstone’. He replied ‘The bishops are not pleased’. ‘Then let the bishops have the babies Mr. Gladstone’ she replied.

At these times, nobody would have imagined that labour analgesia would be as self-evident in conjunction with childbirth as it is in many institutions around the world today. And remifentanil may be one day as self-evident in the labour suite as in the perioperative setting or as pain relief itself during labour and the regimen may further vary depending on the setting in which it is used [49]. However, anaesthesiologists should be cautious and concerned with ensuring that such a valuable method is not discredited with complications occurring due to the fact that safety standards are not guaranteed or cost issues dominate the discussion. We should bear in mind, that remifentanil patient controlled analgesia in labour so far should not be viewed as a poor man's epidural requiring less monitoring as compared to epidural analgesia [50].

Summary

Multiple beneficial effects when compared with conventional opioids contributed to the fact that remifentanil PCA has already gained a place in modern labour analgesia in many institutions.

However, remifentanil retains its potential to cause harm also in the labouring women. In the setting of appropriate precautions, such as one-to-one midwifery care, appropriate monitoring and providing that enough experience exist with this potent opioid including its side effects, remifentanil PCA is a useful option in addition to epidural analgesia and other central neuraxial blocks, provided that adequate safety precautions are met. Thus, for various reasons remifentanil should be viewed as complimentary method to the more potent neuraxial techniques and not as a “poor man's epidural”. Cost-savings may only be realized by reducing vital precautions and thus leading to catastrophic outcomes, with the risk to cast a damning light on this valuable armamentarium for labour analgesia.

Therefore, the authors conclude that economic considerations and potential cost-savings in conjunction with remifentanil PCA may not be appropriate endpoints when studying this valuable method for labour analgesia [51].

Competing interests

AM maintains a quality assurance project for the use of remifentanil PCA as labor analgesic www.remipca.org and provides services for institutions aiming to adopt this method of labor analgesia. PK gives lectures and provides implementation help in conjunction with remifentanil PCA as labor analgesic (academic basis, not for profit).

Authors' contributions

All authors made substantial contributions to the conception of the article. PK wrote a first draft and coordinated the feedback from the co-authors to provide subsequent versions of the article. All authors read and approved the final manuscript.

Authors' information

PK is Consultant anaesthetist and Professor of Anaesthesia at the Department of Anaesthesia and Critical Care. He is responsible for the

anaesthesia services in obstetrics and gynecology at Würzburg University Hospital. TG is Consultant anaesthetist and Professor of Anaesthesia. He is responsible for the anaesthesia services in obstetrics and gynecology at Basel University Hospital. PL is Consultant anaesthetist and Professor of Anaesthesia at the Department of Anesthesiology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium, AM is Consultant anaesthetist at the Department of Anaesthesia, Salem-Spital, Bern, Switzerland, JJ is resident in the Department of Anaesthesia at Würzburg University Hospital, RMM is Consultant anaesthetist. He is responsible for the Critical Care Unit of the Department of Anaesthesia at Würzburg University Hospital. JW is Chief Consultant Neonatologist at University Children's Hospital, Würzburg, Germany. AH is Deputy Director of the Department of Obstetrics and Gynecology at the University Hospital of Würzburg.

Acknowledgements

We appreciate the feedback of colleagues in conjunction with this method of analgesia in order to improve safety and efficacy for this method of pain relief during labor.

Author details

¹Department of Anaesthesia and Critical Care, University Hospitals of Würzburg, Oberdürrbacher Str. 6, Würzburg 97080, Germany. ²Department of Anaesthesia, University Hospital Basel, Spitalstrasse 21, Basel, CH 4031, Switzerland. ³Department of Anesthesiology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium. ⁴Department of Anaesthesia, Salem-Spital, Schänzlistrasse 39, 3000, Bern 25, Switzerland. ⁵University Children's Hospital, Josef-Schneider-Strasse 2, Würzburg 97080, Germany. ⁶Department of Obstetrics and Gynecology, University Hospitals of Würzburg, Josef-Schneider-Strasse 4, Würzburg 97080, Germany.

Received: 22 November 2012 Accepted: 28 June 2013

Published: 2 July 2013

References

- Hodnett ED: Pain and women's satisfaction with the experience of childbirth: a systematic review. *Am J Obstet Gynecol* 2002, **186**:S160–S172.
- ACOG: Pain Relief During Labor. ACOG Committee on Obstetric Practice 2004, Number 295, Last access: 20 November. 2012.
- Gogarten W, Van Aken H, Kessler P, et al: Durchführung von Analgesie- und Anästhesieverfahren in der Geburtshilfe. *Anästh Intensivmed* 2009, **50**:S502–S507.
- Goetzl LM: ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric analgesia and anesthesia. *Obstet Gynecol* 2002, **100**:177–191.
- IASP: Declaration of Montreal: Declaration that Access to Pain Management Is a Fundamental Human Right. Last access: 20 November; 2012. <http://www.iasp-pain.org/PainSummit/DeclarationOfMontreal.pdf>.
- Freeman LM, Bloemenkamp KW, Franssen MT, et al: Remifentanyl patient controlled analgesia versus epidural analgesia in labour. A multicentre randomized controlled trial. *BMC Pregnancy Childbirth* 2012, **12**:63.
- AWMF: S3-Leitlinie Behandlung akuter perioperativer und posttraumatischer Schmerzen. Last access: 20 November; 2012. http://www.awmf.org/uploads/tx_szleitlinien/041-001_S3_Behandlung_akuter_perioperativer_und_posttraumatischer_Schmerzen_aktualisierte_Fassung_04-2009_05-2011.pdf 2009.
- Olofsson C, Ekblom A, Ekman-Ordeberg G, Hjelm A, Irestedt L: Lack of analgesic effect of systemically administered morphine or pethidine on labour pain. *Br J Obstet Gynaecol* 1996, **103**:968–972.
- Tsui MH, Ngan Kee WD, Ng FF, Lau TK: A double blinded randomised placebo-controlled study of intramuscular pethidine for pain relief in the first stage of labour. *Br J Obstet Gynaecol* 2004, **111**:648–655.
- Ullman R, Smith LA, Burns E, Mori R, Dowsell T: Parenteral opioids for maternal pain relief in labour. *Cochrane Database Syst Rev* 2010, (9). CD007396.
- Tveit TO, Halvorsen A, Rosland JH: Analgesia for labour: a survey of Norwegian practice - with a focus on parenteral opioids. *Acta Anaesthesiol Scand* 2009, **53**:794–799.
- Schnabel A, Hahn N, Muellenbach R: Obstetric analgesia in German clinics: Remifentanyl as alternative to regional analgesia. *Anaesthesist* 2011, **60**:995–1001.
- Jankovic K, IASP: Guide to Pain Management in Low-Resource Settings. Chapter 17: Pharmacological Management of Pain in Obstetrics. Last access: 21 November; 2012. <http://www.iasp-pain.org/AM/Template.cfm?Section=Home&Template=/CM/ContentDisplay.cfm&ContentID=12180> 2012.
- Sheikh A, Tunstall ME: Comparative study of meptazinol and pethidine for the relief of pain in labour. *Br J Obstet Gynaecol* 1986, **93**:264–269.
- Nel CP, Bloch B, Rush JM: A comparison of meptazinol and pethidine for pain relief during the first stage of labour. *S Afr Med J* 1981, **59**:908–910.
- Irestedt L: Current status of nitrous oxide for obstetric pain relief. *Acta Anaesthesiol Scand* 1994, **38**:771–772.
- Klomp T, Van Poppel M, Jones L, Lazet J, Di Nisio M, Lagro-Janssen AL: Inhaled analgesia for pain management in labour. *Cochrane Database Syst Rev* 2012, **9**:CD009351.
- Rosen MA: Nitrous oxide for relief of labor pain: a systematic review. *Am J Obstet Gynecol* 2002, **186**:S110–S126.
- Shu Y, Patel SM, Pac-Soo C, et al: Xenon pretreatment attenuates anesthetic-induced apoptosis in the developing brain in comparison with nitrous oxide and hypoxia. *Anesthesiology* 2010, **113**:360–368.
- Volmanen P, Akural E, Raudaskoski T, Ohtonen P, Alahuhta S: Comparison of remifentanyl and nitrous oxide in labour analgesia. *Acta Anaesthesiol Scand* 2005, **49**:453–458.
- Jones R, Pegrum A, Stacey RG: Patient-controlled analgesia using remifentanyl in the parturient with thrombocytopenia. *Anaesthesia* 1999, **54**:461–465.
- Thurlow JA, Waterhouse P: Patient-controlled analgesia in labour using remifentanyl in two parturients with platelet abnormalities. *Br J Anaesth* 2000, **84**:411–413.
- Roelants F, De Franceschi E, Veyckemans F, Lavand'homme P: Patient-controlled intravenous analgesia using remifentanyl in the parturient. *Can J Anaesth* 2001, **48**:175–178.
- D'Onofrio P, Novelli AM, Mecacci F, Scarselli G: The efficacy and safety of continuous intravenous administration of remifentanyl for birth pain relief: an open study of 205 parturients. *Anesth Analg* 2009, **109**:1922–1924.
- Manullang TR, Chun K, Egan TD: The use of remifentanyl for Cesarean section in a parturient with recurrent aortic coarctation. *Can J Anaesth* 2000, **47**:454–459.
- McCarroll CP, Paxton LD, Elliott P, Wilson DB: Use of remifentanyl in a patient with peripartum cardiomyopathy requiring Caesarean section. *Br J Anaesth* 2001, **86**:135–138.
- Heesen M, Klohr S, Hofmann T, et al: Maternal and foetal effects of remifentanyl for general anaesthesia in parturients undergoing caesarean section: a systematic review and meta-analysis. *Acta Anaesthesiol Scand* 2013, **57**:29–36.
- Hill D: Remifentanyl patient-controlled analgesia should be routinely available for use in labour. *Int J Obstet Anesth* 2008, **17**:336–339.
- Lavand'homme P, Roelants F: Patient-controlled intravenous analgesia as an alternative to epidural analgesia during labor: questioning the use of the short-acting opioid remifentanyl. Survey in the French part of Belgium (Wallonia and Brussels). *Acta Anaesthesiol Belg* 2009, **60**:75–82.
- Schnabel A, Hahn N, Broscheit J, et al: Remifentanyl for labour analgesia: a meta-analysis of randomised controlled trials. *Eur J Anaesthesiol* 2012, **29**:177–185.
- Tveit TO, Seiler S, Halvorsen A, Rosland JH: Labour analgesia: a randomised, controlled trial comparing intravenous remifentanyl and epidural analgesia with ropivacaine and fentanyl. *Eur J Anaesthesiol* 2012, **29**:129–136.
- Douma MR, Middeldorp JM, Verwey RA, Dahan A, Stienstra R: A randomised comparison of intravenous remifentanyl patient-controlled analgesia with epidural ropivacaine/sufentanyl during labour. *Int J Obstet Anesth* 2011, **20**:118–123.
- Bonner JC, McClymont W: Respiratory arrest in an obstetric patient using remifentanyl patient-controlled analgesia. *Anaesthesia* 2012, **67**:538–540.
- Pruefer C, Bewlay A: Respiratory arrest with remifentanyl patient-controlled analgesia—another case. *Anaesthesia* 2012, **67**:1044–1045.
- Sneyd R: Remifentanyl on the labour ward. *Anaesthesist* 2012, **67**:1045–1046.
- Sneyd JR: Off-label use of medicines is bad medicine flying the flag of clinical freedom. *Int J Obstet Anesth* 2009, **18**:249–250.
- Bogod DG: Off-licence use of medicines is bad medicine flying the flag of clinical freedom. *Int J Obstet Anesth* 2009, **18**:250–252.
- Frambach T, Wirbelauer J, Schelling P, et al: Patient-controlled intravenous analgesia with remifentanyl as an alternative to epidural analgesia during labor: case series and discussion of medicolegal aspects. *Z Geburtshilfe Neonatol* 2010, **214**:145–150.

39. Kranke P, Schelling P, Frambach T, Wirbelauer J: **Remifentanil-PCA to alleviate labor-pain - a true and safe alternative to epidural labor analgesia?** *Anesthesiol Intensivmed Notfallmed Schmerzther* 2009, **44**:660–663.
40. Kranke P, Lavand'homme P: **The relief of pain in labour and the role of remifentanil.** *Eur J Anaesthesiol* 2012, **29**:116–120.
41. Ismail MT, Hassanin MZ: **Neuraxial analgesia versus intravenous remifentanil for pain relief in early labor in nulliparous women.** *Arch Gynecol Obstet* 2012, **286**:1375–1381.
42. Douma MR, Verwey RA, Kam-Endtz CE, van der Linden PD, Stienstra R: **Obstetric analgesia: a comparison of patient-controlled meperidine, remifentanil, and fentanyl in labour.** *Br J Anaesth* 2010, **104**:209–215.
43. Eisenach JC, Pan PH, Smiley R, Lavand'homme P, Landau R, Houle TT: **Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression.** *Pain* 2008, **140**:87–94.
44. Konopka KH, Van Wijhe M: **Opioid-induced hyperalgesia: pain hurts?** *Br J Anaesth* 2010, **105**:555–557.
45. Lee L, Weinger M: **Anesthesia Patient Safety Foundation Consensus Conference Report.** *Anesth Analg* 2012, **114**:918–919.
46. Greene MF: **Two hundred years of progress in the practice of midwifery.** *N Engl J Med* 2012, **367**:1732–1740.
47. Tveit TO, Halvorsen A, Seiler S, Rosland JH: **Efficacy and side effects of intravenous remifentanil patient-controlled analgesia used in a stepwise approach for labour: an observational study.** *Int J Obstet Anesth* 2013, **22**:19–25.
48. Anonymous: **The Lancet. London: Saturday, May 14, 1853.** *Lancet* 1953, **61**:453.
49. Saunders TA, Glass PS: **A trial of labor for remifentanil.** *Anesth Analg* 2002, **94**:771–773.
50. Hollmann MW, Strumper D, Durieux ME: **The poor man's epidural: systemic local anesthetics for improving postoperative outcomes.** *Med Hypotheses* 2004, **63**:386–9.
51. Volmanen P, Palomaki O, Ahonen J: **Alternatives to neuraxial analgesia for labor.** *Curr Opin Anaesthesiol* 2011, **24**:235–41.

doi:10.1186/1471-2393-13-139

Cite this article as: Kranke et al.: Must we press on until a young mother dies? Remifentanil patient controlled analgesia in labour may not be suited as a "poor man's epidural". *BMC Pregnancy and Childbirth* 2013 13:139.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

